An observational study in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 30 sites in Russia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by AstraZeneca · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 31st largest by enrollment of the 89 observational ones that give a count, is one of 17 that started in 2024, is one of 90 observational ones, and was the 274th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 17 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,024 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 128 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 179 (49%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.
The study consists of a retrospective phase covering 52 weeks and a prospective phase of 24 weeks, involving 2000 patients across approximately 35 cites. Therefore, the aim of the study is to evaluate the clinical and demographic patients' characteristics based on retrospective part and COPD treatment patterns based on prospective part of patients with frequent exacerbations of COPD on dual therapy in the Russian Federation. The study results will be interpreted in the context of an open label, single arm study design. Due to the limited data available on the COPD population in Russia, the characterization of clinical and demographic characteristic of patients based on the retrospective component of the study will enhance the understanding of this patient group and the prospective aspect, which analyses therapeutic approaches, will help to assess physicians' adherence to current recommendations regarding therapy selection for COPD patients on dual therapy with frequent exacerbations.
2000 adult patients with diagnosed moderate-to-severe COPD and ≥2 moderate or ≥1 severe exacerbations in previous 52 weeks despite two inhaled maintenance therapies (LABA/LAMA, ICS/LABA, ICS/LAMA) for at least 6 weeks prior to inclusion and are monitored and treated by pulmonologists or general practitioners
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To describe the baseline Demographic data characterisics of outpatients with moderate and severe COPD.
Demographic data 1. Mean age at the inclusion into the study, and age groups (\<50; 50-65, \>65 years); 2. Mean age at the primary COPD diagnosis; 3. Proportion of men and women; 4. Proportion of patients with each educational status (higher, secondary special, secondary general) at inclusion; 5. Proportion of patients from each residential region of Russia;
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Negative lifestyle factors characterisics of outpatients with moderate and severe COPD.
Negative lifestyle factors 6. Proportion of patients with negative lifestyle factors at inclusion (evaluated on Visit 1 based on patient's interview): a. Proportion of patients with history of smoking (former smoker)/current smokers - applicable for tobacco and e-cigarettes (vapes) smoking; d. Proportion of patients with overeating; e. Proportion of patient with physical inactivity.
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Anthropometry data characterisics of outpatients with moderate and severe COPD.
Anthropometry data 7. Mean body mass index (BMI) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1);
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline COPD drug treatment duration in previous 52 weeks of outpatients with moderate and severe COPD.
9\. Proportion of patients receiving different classes of drugs for treatment of COPD during prior 52 weeks before inclusion. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. SABA alone; 2. ICS alone 3. LABA alone 4. LAMA alone 5. LABA and LAMA 6. ICS and LABA 7. ICS and LAMA 8. LABA and LAMA plus: a) Macrolide antibiotics b) CS
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Cardiovascular diseases of outpatients with moderate and severe COPD.
Cardiovascular diseases 10. Proportion of patients with cardiovascular diseases (heart failure; ischaemic heart disease; myocardial infarction; arrhythmia; stroke; arterial hypertension; peripheral arterial disease; diabetes mellitus (type I, type II); chronic kidney disease (CKD); pulmonary hypertension) at inclusion (diagnosed in medical documentation ever or identified on the Visit 1 via a patient interview);
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline other comorbidities of outpatients with moderate and severe COPD.
Other comorbidities 11. Proportion of patients with atrial fibrillation/flutter, ventricular arrhythmias, other arrhythmia (be calculated in patients with presence of arrhythmia before or on Visit 1); 18. Proportion of patients with different other comorbidities at inclusion (diagnosed in previous 52 weeks or on Visit 1).
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline Blood eosinophils count of outpatients with moderate and severe COPD.
Blood eosinophils count 19. Mean blood eosinophils count (cells/μl) at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1); 20. Proportion of patients with different levels of blood eosinophils count at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1): 1. \<150 cells/μl; 2. ≥150 cells/μl; 3. ≥300 cells/μl.
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline mean smoking index .
applicable for current/former tobacco smokers (pack-years)
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline mean duration of smoking
applicable for current/former e-cigarettes (vapes) smokers (years);
Time frame: 52 weeks of retrospective data before visit 1
To describe the Proportion of patients with overweight
determined as BMI ≥25 kg/m2 at inclusion (in previous 52 weeks (the most recent available value) or evaluated on Visit 1
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline dosages of COPD drug treatment in previous 52 weeks of outpatients with moderate and severe COPD.
Proportion of patients receiving different classes of drugs for treatment of COPD. The following classes of drug or their combinations will be collected. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. dosage SABA alone ; 2. dosage ICS alone 3. dosage LABA alone 4. dosage LAMA alone 5. dosage LABA and LAMA 6. dosage ICS and LABA 7. dosage ICS and LAMA 8. LABA and LAMA plus: a) dosage Macrolide antibiotics b) dosage CS
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with heart failure of outpatients with moderate and severe COPD.
12\. Proportion of patients will be evaluated for each heart failure phenotype based on LVEF - HFrEF, HFmrEF, HFpEF (to be calculated in patients with presence of heart failure before or on Visit 1);
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline data of LVEF of patients with heart failure of outpatients with moderate and severe COPD.
13\. Mean and median value of LVEF, % (to be calculated in patients with presence of heart failure before or on Visit 1 and available data on LVEF based on echocardiography);
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5 of outpatients with moderate and severe COPD.
14\. to be calculated in patients with presence of CKD before or on Visit 1.
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline mean office BP (SBP and DBP) measured at Visit 1 of outpatients with moderate and severe COPD.
15\. this parameter evaluated in total population and in patients with presence of AH before or on Visit 1)
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 1 of outpatients with moderate and severe COPD.
16\. to be evaluated in patients with presence of AH before or on Visit 1;
Time frame: 52 weeks of retrospective data before visit 1
To describe the baseline proportion of patients with various classes of medications used for treatment of CVD of outpatients with moderate and severe COPD.
17\. to be evaluated in patients with at least one cardiovascular disease
Time frame: 52 weeks of retrospective data before visit 1
To describe the proportion of patients receiving different classes of drugs for treatment of COPD between V1 and V2
the proportion of patients with prescribed of the following classes of drug or their combinations. The combinations may be prescribed as separate drugs or fixed combination (of ≥1 drug class in one medication): 1. SABA alone 2. LABA alone 3. LAMA alone 4. ICS alone 5. ICS and LABA 6. ICS and LAMA 7. LABA and LAMA 8. ICS and LABA and LAMA (triple therapy)
Time frame: 24 weeks after visit 1
To describe Healthcare resource utilization during 24-week prospective study follow-up compared to baseline period
7\. Proportion of patients with healthcare resource utilization events due to COPD during 52 weeks prior to inclusion (Visit 1): * Unscheduled outpatient visits; * Emergency department visits/emergency calls; * Hospitalizations. 8. Proportion of patients with healthcare resource utilization events due to COPD occurred from inclusion (Visit 1) to Visit 2: * Unscheduled outpatient visits; * Emergency department visits/emergency calls; * Hospitalizations.
Time frame: 24 weeks after visit 1
To describe changes of Mean forced expiratory volume during 24-week prospective study follow-up compared to baseline
11\. Mean parameters of lung function at inclusion (Visit 1) and Visit 2: a. Mean forced expiratory volume in 1 second (pre- and post-FEV1); 12. change from baseline (Visit 1) to Visit 2: a. Pre- and post-bronchodilator FEV1;
Time frame: 24 weeks after visit 1
To describe Change in CAT score during 24-week prospective study follow-up compared to baseline
13\. Mean baseline in the COPD Assessment Test (CAT) score at inclusion; 14. Mean change from baseline (at inclusion) to 24 weeks (Visit 2) in the CAT score;
Time frame: 24 weeks after visit 1
To describe Newly occurred cardiovascular diseases and other comorbidities during 24-week prospective study follow-up
16\. The proportion of patients with newly occurred cardiovascular diseases (heart failure; ischaemic heart disease; myocardial infarction; arrhythmia; stroke; arterial hypertension; peripheral arterial disease; diabetes mellitus (type I, type II); chronic kidney disease (CKD); pulmonary hypertension; pulmonary embolism) during study follow-up, the analysis includes withdrawn patients; 17. The proportion of patients with newly occurred other (non-cardiovascular) comorbidities during study follow-up, the analysis includes withdrawn patients.
Time frame: 24 weeks after visit 1
To describe Blood eosinophils count during 24-week prospective study follow-up compared to baseline
18\. Mean blood eosinophils count (cells/μl) on Visit 2; 19. Proportion of patients with different levels of blood eosinophils count on Visit 2: 1. \<150 cells/μl; 2. ≥150 cells/μl; 3. ≥300 cells/μl. 20. Mean change in blood eosinophils count (cells/μl) from baseline (Visit 1) to Visit 2.
Time frame: 24 weeks after visit 1
To describe COPD corticosteroid treatment during 24-week prospective study follow-up and change in therapy compared to baseline period
3.Proportion of patients with CS prescribed during the study between Visit 1 and Visit 2 - overall and by type (CS intermittent; CS regularly);
Time frame: 24 weeks after visit 1
To describe Proportion of patients with macrolide antibiotics during 24-week prospective study follow-up and change in therapy compared to baseline period
prescribed during the study between Visit 1 and Visit 2.
Time frame: 24 weeks after visit 1
To describe Proportion of patients with change of inhaled COPD therapy during the study during 24-week prospective study follow-up and change in therapy compared to baseline period
between V1 and V2 compared to the baseline period (change in drug class: SABA alone, LABA alone, LAMA alone, ICS alone, open and fixed combination of ICS, LABA or LAMA, macrolide antibiotics; CS: intermittent or regularly; or starting of triple therapy with ICS/LABA/LAMA);
Time frame: 24 weeks after visit 1
To describe Mean duration of COPD-related hospitalizations during 52 weeks prior to inclusion
will be described at Visit 1
Time frame: 52 weeks of retrospective data before visit 1
To describe Mean duration of COPD-related hospitalizations during 24-week prospective study follow-up compared to baseline period
occurred from inclusion (Visit 1) to Visit 2.
Time frame: 24 weeks after visit 1
To describe changes of Mean forced vital capacity during 24-week prospective study follow-up compared to baseline
* Mean forced vital capacity (FVC) at Visit 1 * Mean FVC change from baseline (Visit 1) to Visit 2
Time frame: 24 weeks after visit 1
To describe changes of Mean post-bronchodilator FEV1/FVC ratio during 24-week prospective study follow-up compared to baseline
* at Visit 1 * change from baseline (Visit 1) to Visit 2
Time frame: 24 weeks after visit 1
To describe Percent of responders using the CAT who achieved MCID (minimal clinically important difference) during 24-week prospective study follow-up compared to baseline
Determined as 2 or more points after 24 weeks from baseline;
Time frame: 24 weeks after visit 1
To describe Mean CS daily dose (mg/day in prednisolone equivalent) during the study between Visit 1 and Visit 2 during 24-week prospective study follow-up and change in therapy compared to baseline period
evaluated in patients with CS prescribed during the study
Time frame: 24 weeks after visit 1
To describe Proportion of patients with CS using for COPD exacerbations treatment during the study
between Visit 1 and Visit 2 during 24-week prospective study follow-up and change in therapy dose compared to baseline period
Time frame: 24 weeks after visit 1
To describe proportion of patients with COPD-related disability present at the inclusion
for each disability group (I, II, III)
Time frame: at visit 1
To describe proportion of patients with COPD-related disability changing during study follow-up
by disability group (I, II, III) assigned at the changing (to be evaluated in patients with disability present at Visit 1)
Time frame: 24 weeks after visit 1
To describe proportion of patients with COPD-related disability newly established during study follow-up
by disability group (I, II, III) assigned at the establishing (to be evaluated in patients with disability absent at Visit 1).
Time frame: 24 weeks after visit 1
To describe proportion of patients with atrial fibrillation/flutter, ventricular arrhythmias, other arrhythmia
be calculated in patients with arrhythmia diagnosed during study follow-up
Time frame: 24 weeks after visit 1
To describe proportion of patients with each heart failure phenotype based on LVEF - HFrEF, HFmrEF, HFpEF
to be calculated in patients with heart failure diagnosed during study follow-up
Time frame: 24 weeks after visit 1
To describe Mean and median value of LVEF, %
to be calculated in patients with heart failure diagnosed during study follow-up and available data on LVEF based on echocardiography;
Time frame: 24 weeks after visit 1
To describe proportion of patients with decompensation of previously diagnosed heart failure
to be calculated in patients with heart failure diagnosed before or at Visit 1;
Time frame: 24 weeks after visit 1
To describe proportion of patients with each CKD stage - C1, C2, C3a, C3b, C4, C5
to be calculated in patients with CKD diagnosed during study follow-up;
Time frame: 24 weeks after visit 1
To describe proportion of patients with each type of stroke occurred during the study follow-up - ischemic, hemorrhagic
to be calculated in patients with stroke occurred during study follow-up;
Time frame: 24 weeks after visit 1
To describe mean office BP (SBP and DBP) measured at Visit 2
this parameter evaluated in total population and in patients with AH diagnosis established at any time;
Time frame: 24 weeks after visit 1
To describe proportion of patients with AH by distribution by AH stage (I, II, III), AH degree (1st, 2nd, 3rd) and risk category at Visit 2
to be evaluated in patients with AH diagnosis established at any time;
Time frame: 24 weeks after visit 1
To describe proportion of patients with various classes of medications used for treatment of CVD
to be evaluated in patients with at least one cardiovascular disease from listed above;
Time frame: 24 weeks after visit 1
Ran from Dec 2024 to primary completion in Jun 2026, 18 months.
Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 18 months is below that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →